Sisu Pharma

Sisu Pharma is a private, preclinical-stage biotech founded in 2018 and based in San Diego, California. The company is pioneering a novel therapeutic strategy by directly targeting the transcription factor HSF1, a historically 'undruggable' master regulator of cellular stress protection. Its proprietary HI-LiTe platform enables the discovery of compounds that can either degrade or activate HSF1, with applications in oncology, neurodegeneration, and infection. Led by a team of seasoned scientists and drug developers, Sisu is advancing first-in-class compounds that have shown exceptional efficacy in resistant cancer models.

HI-LiTe (HSF1 Interacting-Ligand Technology) - a proprietary platform designed to directly target the transcription factor Heat Shock Factor 1 (HSF1) with small molecules, enabling the discovery of selective HSF1 degraders and activators.

Competition includes companies that have indirectly targeted the HSF1 pathway through downstream chaperones like Hsp90 (e.g., earlier programs from Pfizer, BMS), though these faced toxicity challenges. Sisu's direct HSF1 targeting approach is novel and could face future competition from other biotechs pursuing similar strategies or alternative protein degradation technologies.